Physician profile
Robin Figliola
NPI 1841290343
$2,866.21
in general payments reported to CMS, 2019-2025
31 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $417 · 2021: $734 · 2023: $259 · 2024: $389 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $379.59 | 2019-2021 | |
| Lilly USA, LLC | $261.94 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $231.18 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $214.13 | 2019-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $188.70 | 2021-2024 | |
| Pfizer INC. | $188.09 | 2019-2025 | |
| Glaxosmithkline, LLC. | $174.58 | 2019-2023 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $163.82 | 2021 | |
| Exact Sciences Corporation | $153.23 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.33 | 2019-2021 | |
| Abbott Laboratories | $104.18 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $101.93 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.65 | 2024-2025 | Xifaxan, Relistor |
| Novo Nordisk INC | $98.48 | 2019-2020 | |
| Alkermes, INC. | $45.46 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $38.57 | 2019 | |
| Astellas Pharma US INC | $31.16 | 2023 | Veozah |
| Hikma Pharmaceuticals USA | $27.49 | 2019 | |
| Amgen INC. | $27.06 | 2019 | |
| Qiagen, LLC | $24.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $19.86 | 2024 | |
| Phadia US INC. | $17.24 | 2025 | Immunocap |
| Inspire Medical Systems, INC. | $16.61 | 2024 | Inspire |
| Sanofi Pasteur INC. | $16.04 | 2023 | |
| Strongbridge US INC. | $15.19 | 2019 | |
| Allergan, INC. | $14.97 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.78 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $14.75 | 2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $14.42 | 2021 | |
| Opko Pharmaceuticals, LLC | $13.93 | 2023 | Rayaldee |
| Nabriva Therapeutics, Plc | $13.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Figliola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.